Sattva S. Neelapu, MD, Talks Safety and Efficacy of ALLO-501/647 for Patients With LBCL


Dr Neelapu, MD Anderson Cancer Center, Houston, Texas, talks about early findings from the ALPHA study which suggest that ALLO-501, a genetically modified anti-CD19 CAR T-cell agent, and ALLO-647, an anti-CD52 monoclonal antibody, are safe and may be effective for use in patients with large B-cell lymphoma (LBCL) or follicular lymphoma.

Stay in the know.
OncNet Newsletter